We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Explains how commissioners and health professionals can use data and analysis for decisions about cardiovascular services and interventions.
Sets out Public Health England's (PHE) initiatives for cardiovascular disease (CVD) prevention.
These reports assess cardiovascular disease in the south-west, focusing on risk factors, heart disease, stroke, kidney disease and diabetes.
A professional resource on improving the detection and treatment of the high-risk conditions atrial fibrillation, high blood pressure and high cholesterol
Advice for medical professionals to use when assessing drivers with cardiovascular disorders.
A resource to help commissioners provide cost-effective interventions to prevent cardiovascular disease.
Data and analysis of cardiovascular disease (CVD) prevalence, variation, treatment and outcomes in clinical commissioning groups (CCG) areas.
Update of cardiovascular disease (CVD) profile indicators for heart disease, diabetes, kidney disease and stroke data for commissioning organisations.
This publication brings together Public Health England's (PHE’s) broad-ranging work in addressing cardiovascular disease.
Evidence and guidance to help healthcare professionals to prevent heart attacks, strokes and dementia and to improve cardiovascular health.
Update of cardiovascular disease (CVD) data looking at heart disease, diabetes, kidney disease and stroke.
We inform healthcare professionals of new risk minimisation measures for JAK inhibitors used to treat chronic inflammatory disorders, consistent with the measures introduced for tofacitinib (Xeljanz) in 2020 and 2021. This advice affects abrocitinib (Cibinqo▼), baricitinib (Olumiant), upadacitinib (Rinvoq▼), and...
Update of cardiovascular disease (CVD) profile indicators for stroke data for clinical commissioning groups.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.